|
WO2020229470A1
|
|
Process and intermediates for the preparation of eldecalcitol
|
|
EP3808335A1
|
|
Compositions for topical administration
|
|
SG11202100575QA
|
|
Pyridopyrimidines as histamine h4-receptor inhibitors
|
|
EP3725298A1
|
|
Stable and preserved pharmaceutical compositions of bilastine
|
|
BR112020014265A2
|
|
OPHTHALMIC COMPOSITIONS ONCE A DAY OF BENZIMIDAZOL COMPOUNDS
|
|
AR113993A1
|
|
FORMULATION ONCE A DAY OF HYDROSMINE
|
|
AU2018353360A1
|
|
Aqueous compositions comprising bilastine and mometasone
|
|
EP3599235A1
|
|
Process and intermediates for the preparation of bilastine
|
|
EP3378508A1
|
|
Container for cannulas
|
|
EP3170816A1
|
|
Supersaturated compositions of benzimidazole compounds
|
|
EP3170817A1
|
|
Co-crystals of benzimidazole compounds
|
|
EP3053598A1
|
|
Calcifediol soft capsules
|
|
EP3040334A1
|
|
New benzimidazole derivatives as antihistamine agents
|
|
TW201307254A
|
|
Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
|
|
KR20130082453A
|
|
Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
|
|
EP2465498A1
|
|
Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
|
|
EP2390248A1
|
|
Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
|
|
JP2010013472A
|
|
POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
|
|
TW201010988A
|
|
5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
|
|
US2009312376A1
|
|
5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
|
